Current Peptide HIV Type-1 Fusion Inhibitors

  title={Current Peptide HIV Type-1 Fusion Inhibitors},
  author={Wei Pang and Siu-cheung Tam and Yong-tang Zheng},
  journal={Antiviral Chemistry and Chemotherapy},
  pages={1 - 18}
There are now 26 antiretroviral drugs and 6 fixed-dose combinations, including reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors and fusion (or entry) inhibitors, approved by the US Food and Drug Administration for clinical use. Although they are clinically effective when used in combination, none of the existing drugs are considered ideal because of toxic side effects and the ascendance of inducing drug-resistant mutants. Development of new antiviral agents is… 

Figures and Tables from this paper

Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: an in silico drug repurposing study
It can be stated that Enf can act as a strong SARS-CoV-2 fusion inhibitor and demonstrates the potential to enter the clinical trial phase of COVID-19.
Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action
PEGylated C34 with broad-spectrum anti-HIV-1 activity and prolonged half-life can be further developed as a peptide fusion inhibitor-based long-acting anti-hIV drug for clinical use to treat HIV-infected patients who have failed to respond to current anti-retrovirus drugs.
Use of Retroviral Peptide Libraries for the Identification of Novel Cellular Targets of HIV-1 and the Discovery of Novel Inhibitors
The adaptation of retroviral technology in order to discover novel peptide inhibitors of HIV-1 or HIV- 1-interacting proteins is described, including the development of high-complexity libraries of random peptides, targeted to specific cellular compartments.
The Effect of N-Terminal Cyclization on the Function of the HIV Entry Inhibitor 5P12-RANTES
It is shown that cyclization is not necessary for the potency of this protein and that several replacement terminal amino acids produce nearly-equally potent HIV inhibitors while remaining CC chemokine receptor 5 (CCR5) antagonists.
Pharmaceutical Approaches to HIV Treatment and Prevention
Currently available anti‐HIV drugs and their combinations for treatment, new molecules under clinical development and prevention methods, and drug delivery formats are summarized as well as associated challenges and alternative approaches for the future are discussed.
SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells
The development entry inhibitors targeting the S protein, as well as the most promising host targeting strategies involving TMPRSS2 and CatB/L, which have been exploited so far against CoVs and other related viruses are discussed.
Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors
The first potent and broad VL sdAb fusion inhibitor of HIV infection is developed, and insights into engineering strategies that could be explored to enhance the development of antiviral drugs are given.
A Novel Enzyme-Linked Immunosorbent Assay for Screening HIV-1 Fusion Inhibitors Targeting HIV-1 Gp41 Core Structure
A novel, rapid, and economic enzyme-linked immunosorbent assay was established, which can be developed for high-throughput screening of HIV-1 fusion inhibitors.
Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides.
This review focuses on rational development of anti-HIV-1 peptides based on mapping viral-host and viral-viral protein interactions all across the HIV-1 replication cycle.
Insights of inhibition mechanism of sifuvirtide and MT-sifuvirtide against wild and mutant HIV-1 envelope glycoprotein41: a molecular dynamics simulation and binding free energy study
Intermolecular interactions reveal that MTSFT forms more strong interactions with NHR of gp41 than SFT, which is critical for six-helix bundle stabilisation, which explained the detailed functional role of MT-hook against gp41 fusion at the molecular level.


HIV entry inhibitors
HIV entry inhibitors: mechanisms of action and resistance pathways.
Entry inhibitors represent a new generation of antivirals for the treatment of HIV infection which block the attachment of HIV gp120 to either the CD4 T cell receptor or the CCR5/CXCR4 co-receptors.
Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains
CP32M is exceptionally potent (at low picomolar level) against infection by a panel of HIV-1 mutants highly resistant to T20 and C34, suggesting that CP32M can be further developed as an antiviral therapeutic against multidrug resistant HIV- 1.
Resistance to enfuvirtide, the first HIV fusion inhibitor.
Fusion inhibitors block the last step in the three-step viral entry process consisting of attachment, co-receptor binding and fusion, thereby preventing viral capsid entry into the host cell.
Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor*
Sifuvirtide has potential to become an ideal fusion inhibitor for treatment of HIV/AIDS patients, including those with HIV-1 strains resistant to T20, as well as the results from Phase Ia clinical studies, which suggest that sifuvIRTide has a different mechanism of action from that of T20.
Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during Therapy with the T20 Fusion Inhibitor
A mechanistic model for the dependence of HIV-1 entry on the T20 peptide is proposed and it is reported for the first time the emergence of drug-dependent viruses with mutations in both the HR1 and HR2 domains of envelope glycoprotein 41.
Inhibition of Human Immunodeficiency Virus Type 1 Entry in Cells Expressing gp41-Derived Peptides
The first gene therapeutic strategy targeting entry of a broad range of HIV type 1 (HIV-1) variants, and this optimized construct effectively inhibited virus replication in cell lines and primary blood lymphocytes, suggests that membrane-anchored antiviral C peptides have a mode of action similar to that of free gp41 C peptide.
Sifuvirtide, a potent HIV fusion inhibitor peptide.